ClinicalTrials.gg
CompletedNCT07202663Updated Apr 6, 2026

Study of BB-025, Alone and After BB-031, in Healthy Volunteers

A Phase 1 interventional study of BB-025 and BB-031 in Pharmacodynamics, Pharmacokinetics and Healthy Volunteers, sponsored by Basking Biosciences, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Basking Biosciences, Inc. · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 122 studies in Stroke with a site in Australia — 22 open to participants now, 29 under way, 11 of them phase 3. Stroke · Australia.

Enrollment
88th of 108
72 · median 569
Started
2025
with 7 others
Phase 1
5 of 122
none open now
Registered
119th of 122
by date

Among the 122 studies in Stroke with a site in Australia, this one is the 88th largest by enrollment of the 108 interventional ones that give a count, is one of 8 that started in 2025, is one of 5 in phase 1, and was the 119th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

22 of the 122 studies in Stroke with a site in Australia are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Stroke with a site in Australia, or all of them as a file.
02

Study summary

The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031. Researchers will compare BB-025 to placebo (a look-alike substance that contains no drug) both on its own and after being given a single dose of BB-031 to assess the use of BB-025 as a reversal agent.

In the first part of the study, participants will receive a single dose of BB-025 or placebo. They will be followed for 28 days to check if they have any symptoms.

In the second part of the study, participants will receive a single dose of BB-031 and then be given either BB-025 or placebo. These participants will also be followed for 28 days to check if they have any symptoms.

03

Conditions studied

  • Pharmacodynamics
  • Pharmacokinetics
  • Healthy Volunteers

Keywords

  • Basking Biosciences
  • BB-025
  • BB-031
  • Reversal agent
  • Stroke
  • Acute Ischemic Stroke
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-55 years of age
  • Ability to provide written consent
  • Weight 50-100 kg with 18-32 kg/m2
  • Willingness to use
  • Negative results for alcohol and drugs of abuse

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Familial bleeding disorder or individual or family history of bleeding diathesis or coagulopathy
  • Females with active menstruation on day of dosing
  • Use of prescription medications known to affect function
  • Use of NSAIDs, aspirin, anti-platelet or anti-coagulation therapy within 10 days of dosing
  • to anticoagulation or increased bleeding risks
  • History of thrombocytosis, high platelet count, intracranial bleeding, aneurysm, stroke, vascular disease
  • History of peptic ulcer disease, gastrointestinal or genitourinary bleed, severe trauma, fracture, major surgery of of parenchymal organ within past 3 months
  • Planned surgery during the study
  • Any abnormality at screening
  • Use of drug in past 30 days or 5 half lives
  • Concurrent enrollment in another clinical study or more than 4 clinical studies in past 12 months
  • Any prior history of substance abuse or treatment or positive urine screen for drugs of abuse or positive breathalyzer test
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    Single Ascending Dose BB-025

    Drug: BB-025, Investigational Drug

    Drug: BB-025

  • Placebo comparator
    Single Dose Placebo

    Drug: Matched placebo to BB-025 cohorts

    Drug: BB-025

  • Experimental
    Single Dose BB-031

    Drug: BB-031, Investigational Drug

    Drug: BB-031

Interventions

  • DrugBB-025

    Reversal agent for BB-031

  • DrugBB-031

    RNA aptamer

06

What researchers measure

Primary outcomes

  1. Safety as assessed by adverse events (AEs)

    Incidence of treatment-emergent AEs

    Time frame: From dosing of study drug to final visit (Day 28)

Secondary outcomes

  1. Pharmacokinetics as measured by BB-025 plasma levels

    Plasma concentrations of BB-025 (after single dose of drug)

    Time frame: From dosing to 24 hours after dosing

  2. Pharmacokinetics as measured by BB-031 plasma levels

    Plasma concentrations of BB-031 (after single dose of drug)

    Time frame: From dosing to 24 hours after dosing

  3. Pharmacokinetics as measured by BB-025/BB-031 Complex plasma levels

    Plasma concentration of BB-025/BB-031 Complex after a single dose of each drug

    Time frame: From dosing of BB-031 through 24 hours after dosing of BB-025

  4. Plasma von Willebrand Factor (vWF) Levels

    Level of vWF following administration of study drug

    Time frame: From dosing of BB-031 or BB-025 to 24 hours after dosing of BB-025

  5. Platelet Function

    Whole blood platelet function closure times

    Time frame: From dosing of BB-031 or BB-025 to 24 hours after BB-025 dosing

07

Study locations

1 site
  • Scintia Clinical Research Ltd
    Randwick, New South Wales, Australia
08

References and documents

Individual participant data

Plan to share: No — Publication from this study not anticipated to need IPD data to be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Mar 2026, 4 months.

Of 26 industry-sponsored phase 1 interventional studies under Stroke, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Oct 2, 2025
StartActual
Nov 5, 2025
Primary completionActual
Mar 18, 2026
CompletionActual
Mar 18, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07202663
Lead sponsor
Basking Biosciences, Inc.
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Nov 5, 2025
Primary completion
Mar 18, 2026
Completion
Mar 18, 2026
Last update
Apr 6, 2026

Study contacts

Chris Argent, MD
principal investigator · Scientia Clinical Research Limited

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion